Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma

Journal of Clinical Oncology

Volumn 29, Issue 3, 2011, Pages 330-336

  Okada, Hideho ^a   Kalinski, Pawel ^a   Ueda, Ryo ^a   Hoji, Aki ^a   Kohanbash, Gary ^a   Donegan, Teresa E ^a   Mintz, Arlan H ^a   Engh, Johnathan A ^a   Bartlett, David L ^a   Brown, Charles K ^a   Zeh, Herbert ^a   Holtzman, Matthew P ^a   Reinhart, Todd A ^a   Whiteside, Theresa L ^a   Butterfield, Lisa H ^a   Hamilton, Ronald L ^a   Potter, Douglas M ^a   Pollack, Ian F ^a   Salazar, Andres M ^a   Lieberman, Frank S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; CHEMOKINE; CYTOKINE; DENDRITIC CELL VACCINE; EPITOPE; GLIOMA ASSOCIATED ANTIGEN; INTERLEUKIN 12; LYSINE; MESSENGER RNA; POLYCYTIDYLIC ACID; POLYINOSINIC ACID; SYNTHETIC PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTOMA; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG FATALITY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MALE; MYALGIA; OLIGODENDROGLIOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR RECURRENCE; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CARBOXYMETHYLCELLULOSE SODIUM; CD8-POSITIVE T-LYMPHOCYTES; CELL POLARITY; DENDRITIC CELLS; EPITOPES; FEMALE; GLIOMA; HUMANS; INTERFERON INDUCERS; INTERLEUKIN-12; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; POLY I-C; POLYLYSINE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; VACCINES, SUBUNIT;

EID: 79951978155     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.7744     Document Type: Article

References (57)

1. Liau LM, Prins RM, Kiertscher SM, et al: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515-5525, 2005 (Pubitemid 41060828)
2. Wheeler CJ, Black KL, Liu G, et al: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955-5964, 2008
3. De Vleeschouwer S, Fieuws S, Rutkowski S, et al: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098-3104, 2008
4. Izumoto S, Tsuboi A, Oka Y, et al: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J. Neurosurg 108:963-971, 2008 (Pubitemid 351656845)
5. Okada H, Lieberman FS, Walter KA, et al: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5:67, 2007
6. Okada H, Lieberman FS, Edington HD, et al: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: Preliminary observations in a patient with a favorable response to therapy. J Neurooncol 64:13-20, 2003 (Pubitemid 36992456)
7. Kikuchi T, Akasaki Y, Abe T, et al: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27:452-459, 2004 (Pubitemid 39447353)
8. Yamanaka R, Homma J, Yajima N, et al: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. Clin Cancer Res 11:4160-4167, 2005 (Pubitemid 40791581)
9. Sampson JH, Archer GE, Mitchell DA, et al: An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8:2773-2779, 2009
10. Nishimura F, Dusak JE, Eguchi J, et al: Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: Critical roles of IFN-inducible protein-10. Cancer Res 66:4478-4487, 2006
11. Fujita M, Zhu X, Ueda R, et al: Effective Immunotherapy against murine gliomas using type 1 polarizing dendritic cells: Significant roles of CXCL10. Cancer Res 69:1587-1595, 2009
12. Sasaki K, Zhu X, Vasquez C, et al: Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 67:6451-6458, 2007 (Pubitemid 47037530)
13. Pollack IF, Finkelstein SD, Woods J, et al: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346:420-427, 2002 (Pubitemid 34437697)
14. Smith JS, Tachibana I, Passe SM, et al: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246-1256, 2001 (Pubitemid 32816199)
15. Watchmaker PB, Berk E, Muthuswamy R, et al: Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol 184:591-597, 2010
16. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al: α-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934-5937, 2004 (Pubitemid 39129387)
17. Butowski N, Chang SM, Junck L, et al: A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: A North American Brain Tumor Consortium (NABTC01-05). J Neurooncol 91:175-182, 2009
18. Butowski N, Lamborn KR, Lee BL, et al: A North American Brain Tumor Consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 91:183-189, 2009
19. Salazar AM, Levy HB, Ondra S, et al: Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: An open pilot study. Neurosurgery 38:1096-1103, 1996
20. Zhu X, Nishimura F, Sasaki K, et al: Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5:10, 2007
21. Zhu X, Fallert-Junecko B, Fujita M, et al: Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners. Cancer Immunol Immunother 59:1401-1409, 2010
22. Okano F, Storkus WJ, Chambers WH, et al: Identification of a novel HLA-A*0201 restricted cytotoxic T lymphocyte epitope in a human glioma associated antigen, interleukin-13 receptor 2 chain. Clin Cancer Res 8:2851-2855, 2002 (Pubitemid 35025729)
23. Eguchi J, Hatano M, Nishimura F, et al: Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res 66:5883-5891, 2006 (Pubitemid 43927143)
24. Hatano M, Eguchi J, Tatsumi T, et al: EphA2 as a glioma-associated antigen: A novel target for glioma vaccines. Neoplasia 7:717-722, 2005
25. Hatano M, Kuwashima N, Tatsumi T, et al: Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2:40, 2004
26. Pelloski CE, Mahajan A, Maor M, et al: YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11:3326-3334, 2005 (Pubitemid 40627883)
27. Nutt CL, Betensky RA, Brower MA, et al: YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11:2258-2264, 2005 (Pubitemid 40490185)
28. Liu G, Ying H, Zeng G, et al: HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64:4980-4986, 2004 (Pubitemid 38924546)
29. Salgaller ML, Marincola FM, Cormier JN, et al: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749-4757, 1996 (Pubitemid 26338080)
30. Alexander J, Sidney J, Southwood S, et al: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751-761, 1994
31. Kirkwood JM, Lee S, Moschos SJ, et al: Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group phase II trial E1696. Clin Cancer Res 15:1443-1451, 2009
32. Weber J, Boswell W, Smith J, et al: Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 31:215-223, 2008
33. Melanoma Study Group of the Mayo Clinic Cancer C, Celis E: Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: Evidence of systemic immune dysfunction. Cancer 110:203-214, 2007
34. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408, 2001 (Pubitemid 34164012)
35. Szczepanski MJ, Czystowska M, Szajnik M, et al: Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69:3105-3113, 2009
36. Fallert BA, Reinhart TA: Improved detection of simian immunodeficiency virus RNA by in situ hybridization in fixed tissue sections: Combined effects of temperatures for tissue fixation and probe hybridization. J Virol Methods 99:23-32, 2002 (Pubitemid 33000380)
37. Muthuswamy R, Urban J, Lee JJ, et al: Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 68:5972-5978, 2008
38. Zhu X, Fallert-Junecko BA, Fujita M, et al: Poly-ICLC promotes the infiltration of vaccine-induced T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners. Cancer Immunol Immunother 59:1401-1409, 2010
39. Kalinski P, Hilkens CM, Snijders A, et al: IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 159:28-35, 1997 (Pubitemid 127493681)
40. Kalinski P, Schuitemaker JH, Hilkens CM, et al: Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 162:3231-3236, 1999 (Pubitemid 29313569)
41. Okada H, Kohanbash G, Zhu X, et al: Immunotherapeutic approaches for glioma. Crit Rev Immunol 29:1-42, 2009
42. Rodrigues JC, Gonzalez GC, Zhang L, et al: Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 12:351-365, 2010
43. Ogden AT, Horgan D, Waziri A, et al: Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery 59:902-909, 2006 (Pubitemid 44579657)
44. Debinski W, Gibo DM: Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 6:440-449, 2000
45. Debinski W, Gibo DM, Hulet SW, et al: Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5:985-990, 1999 (Pubitemid 29233211)
46. Liu F, Park PJ, Lai W, et al: A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66:10815-10823, 2006 (Pubitemid 44876977)
47. Saikali S, Avril T, Collet B, et al: Expression of nine tumour antigens in a series of human glioblastoma multiforme: Interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J. Neurooncol 81:139-148, 2007 (Pubitemid 44963972)
48. Monsurro V, Nagorsen D, Wang E, et al: Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol 168:5933-5942, 2002 (Pubitemid 34556184)
49. O'Connell KA, Bailey JR, Blankson JN: Elucidating the elite: Mechanisms of control in HIV-1 infection. Trends Pharmacol Sci 30:631-637, 2009
50. Chianese-Bullock KA, Pressley J, Garbee C, et al: MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 174:3080-3086, 2005 (Pubitemid 40279730)
51. Slingluff CL Jr, Petroni GR, Olson W, et al: Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26:4973-4980, 2008
52. Kalinski P, Okada H: Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumors. Semin Immunol 22:173-182, 2010
53. Gilliet M, Kleinhans M, Lantelme E, et al: Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood 102:36-42, 2003 (Pubitemid 36759633)
54. Bedrosian I, Mick R, Xu S, et al: Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21:3826-3835, 2003 (Pubitemid 46606238)
55. Cohen MH, Shen YL, Keegan P, et al: FDA drug approval summary: Bevacizumab (Avastin(R)) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131-1138, 2009
56. Vredenburgh JJ, Desjardins A, Herndon JE, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Res 13:1253-1259, 2007 (Pubitemid 46424067)
57. Vredenburgh JJ, Desjardins A, Herndon JE, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007 (Pubitemid 350086473)